Skip to main content
. 2023 Jan 12;112(2):197–217. doi: 10.1007/s00223-022-01054-z
Given that the appropriate technology is not available at the moment, the group does not currently recommend this biomarker in clinical trials. Nevertheless, as a clinically promising biomarker, developing a widely available and accurate method for CAF determination could modify this recommendation